Belite Bio Reports FDA Review Extension for Tinlarebant
San Diego, California, United States, November 20, 2026 Belite Bio, Inc. has announced that the U.S. Food and Drug...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
San Diego, California, United States, November 20, 2026 Belite Bio, Inc. has announced that the U.S. Food and Drug...
San Diego, California, U.S., September 8, 2026 Belite Bio has announced the submission of a New Drug Application (NDA)...
Cambridge, Massachusetts — September 3, 2026 Alkeus Pharmaceuticals announced the publication of TEASE-1 efficacy and safety results in JAMA...
TAIWAN, August 12, 2026 Senhwa Biosciences, Inc. has announced new research findings involving its investigational cancer drug Pidnarulex (CX-5461),...
SAN DIEGO, California, August 11, 2026 Belite Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
SAN DIEGO, July 20, 2026 Belite Bio, Inc. (NASDAQ: BLTE) announced additional positive secondary endpoint data from its Phase...
DURHAM, N.C., July 9, 2026 Atsena Therapeutics announced the selection of ATSN-401 as its lead clinical candidate for the...
SAN DIEGO, July 6, 2026 Belite Bio announced that new clinical data from its Phase 3 DRAGON trial evaluating...
DALLAS, May 11, 2026 Nanoscope Therapeutics announced multiple scientific presentations at the American Society of Gene and Cell Therapy...
BOSTON, MASSACHUSETTS, May 04, 2026 Ascidian Therapeutics has announced the completion of the adult dose escalation phase in its...
